Indonesia

Phase: Control.

I. EPIDEMIOLOGICAL PROFILE
Population (UN Population Division)

High transmission ( 1 case per 1000 population) Low transmission (0-1 cases per 1000 population) Malaria-free (0 cases) Total Parasites and vectors Major plasmodium species: Major anopheles species:

2010 88 800 000 16 800 000 134 000 000 239 600 000

% 37 7 56

Indian Ocean Australia

Insufcient data 0 01 110 1050 50100 100

P. falciparum (53%), P. vivax An. sundaicus, balabacensis, maculatus, Maculatus, farauti, subpictus

Distribution of conrmed malaria cases (per 1 000 population)

II. INTERVENTION POLICIES AND STRATEGIES

Intervention WHO-recommended policies/strategies Yes/No Year adopted Yes No Yes No NA Yes Yes Yes Yes Yes 2006 1959 2007 2005 2004 2004 Antimalarial policy First-line treatment of unconrmed malaria First-line treatment of P. falciparum Treatment failure of P. falciparum Treatment of severe malaria Treatment of P. vivax Medicine AS-AQ/DHA-PP+PQ QN+D+PQ AM ;AS ;QN
AS-AQ/DHA-PP+PQ(14d)

Year adopted 2008 2004 2004 2004

ITNs/ LLINs: distributed free of charge ITN ITNs/ LLINs: distributed to all age groups IRS is recommended IRS DDT is used for IRS IPT used to prevent malaria during pregnancy IPT Patients of all ages should receive diagnostic test RDTs used at community level Case ACT is free for all ages in public sector management Pre-referral treatment with recommended medicines Oral artemisinin-based monotherapies are not registered

Therapeutic efcacy tests (therapeutic or parasitological failure, %) Medicine Year No. of Studies Min Median Max AS+AQ 20032006 8 0 8.8 24.1 DHA-PPQ 20042008 3 2.7 4.1 4.8 Expenditure by intervention in 2010

Follow-up 28 days 42 days

III. FINANCING Government and external nancing

Contribution (US$m) 50 40 30 20 10 0 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 Government* Global Fund World bank USAID/PMI WHO/UNICEF
*Budget: costs for sub-national level, health systems, human resources, etc not included.

Insecticide & spraying materials ITNs Diagnostics Antimalarial medicines Monitoring and evaluation Human resources & technical assistance Others Management and other costs

IV. COVERAGE Coverage of ITN and IRS

Households or population (%) 100 80 60 40 20 0 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 Modelled % of households >=1 ITN All ages who slept under an ITN Households with at least one ITN Population at risk protected with IRS Cases (%)
Source: MICS 2000, DHS 2007.

Cases tested and ACT delivered: Programme data (public sector) 100 80 60 40 20 0 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 Suspected cases tested Cases treated with any antimalarial P.P. falciparum cases with potentially f cases treated ACT * treated with ACT Conrmed cases, admissions and deaths (per 100 000) 2.5 2.0 ABER (%) 1.5 1.0 0.5 1000.0 Cases and deaths (log) 100.0 10.0 1.0 0.1 0.0 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 Admissions Deaths Conrmed cases

V. IMPACT Malaria test positivity rate and ABER

40 35 30 25 20 15 10 5 0

Positivity rate ( %)

0.0 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 ABER (Micr. & RDT) RDT positivity rate Slide positivity rate

130

World Malaria report 2011